Talk:Orforglipron
Discussion page·2 threads·no archives
This is the discussion page for the article Orforglipron. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.
Cross-trial comparison in the last sectionResolved
The comparison with semaglutide and tirzepatide figures is exactly the kind of cross-trial reading this wiki tells people not to do elsewhere. — OrforglipronOona (talk) 10:10, 2 May 2026 (UTC)
Fair, and the sentence now says so in its own words: broadly comparable, but cross-trial comparison is unreliable and phase 3 is the test. Removing it entirely would leave a reader without the orientation they came for. — ForestPlotFinn (talk) 13:35, 2 May 2026 (UTC)
That works — the caveat is in the same sentence rather than a paragraph later. ✓ Done — OrforglipronOona (talk) 09:20, 3 May 2026 (UTC)
Species selectivityDone
The species-selectivity point is a nice concrete illustration of why small-molecule work at class B receptors is hard, and it is not in most summaries. Worth keeping. — ReceptorRhoda (talk) 11:45, 14 March 2026 (UTC)
As a reader without a pharmacology background, that paragraph was the one that made the difference between the two approaches click for me. ✓ Done — CuriousCallum (talk) 15:05, 14 March 2026 (UTC)